Shanghai Xiao Fang Pharmaceutical Co.,Ltd. (SHA:603207)
21.95
+0.29 (1.34%)
Jul 29, 2026, 4:00 PM EDT
SHA:603207 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 541.9 | 525.28 | 474.58 | 471.87 | 456.89 | 401.77 |
Revenue Growth | 13.19% | 10.68% | 0.57% | 3.28% | 13.72% | 11.22% |
Gross Profit Gross Profit Growth | 345.56 | 341.25 | 311.3 | 308.8 | 269.45 | 254.43 |
Operating Income Operating Income Growth | 235.35 | 238.19 | 233.49 | 230.48 | 195.85 | 142.84 |
Net Income Net Income Growth | 203.65 | 207.49 | 205.27 | 203.63 | 175.18 | 126.27 |
Earnings Per Share EPS Growth | 1.27 | 1.29 | 1.53 | 1.70 | 1.46 | 1.05 |
EPS Growth | -13.58% | -15.69% | -10.00% | 16.44% | 39.05% | - |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
East China East China Growth | 182.77 |
North China North China Growth | 69.59 |
South China South China Growth | 85.52 |
Southwest Southwest Growth | 59.12 |
Central China Central China Growth | 58.87 |
Northeast Northeast Growth | 45.23 |
Northwest Northwest Growth | 23.4 |
Overseas Overseas Growth | 0.21 |
Total Total Growth | 524.7 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 646.48 | 647.59 | 883.43 | 288.52 | 168.93 | 208.01 |
Total Debt Total Debt Growth | 7.7 | 2.5 | 2.32 | 0.86 | 0.88 | 1.27 |
Net Cash (Debt) Net Cash Growth | 638.78 | 645.08 | 881.11 | 287.65 | 168.05 | 206.74 |
Net Cash Growth | -30.00% | -26.79% | 206.31% | 71.17% | -18.71% | 83.45% |
Net Cash Per Share Net Cash Per Share Growth | 3.98 | 4.01 | 6.57 | 2.40 | 1.40 | 1.72 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 152.91 | 160.8 | 212.21 | 200.26 | 137.2 | 179.51 |
Capital Expenditures CapEx Growth | -82.29 | -54.24 | -83.94 | -80.15 | -61.59 | -12.48 |
Free Cash Flow Free Cash Flow Growth | 70.62 | 106.56 | 128.27 | 120.11 | 75.61 | 167.03 |
Free Cash Flow Growth | -35.50% | -16.93% | 6.79% | 58.86% | -54.73% | 20.59% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 63.77% | 64.96% | 65.59% | 65.44% | 58.97% | 63.33% |
Operating Margin | 43.43% | 45.35% | 49.20% | 48.84% | 42.86% | 35.55% |
Pretax Margin | 43.71% | 45.92% | 50.47% | 50.26% | 45.10% | 38.47% |
Profit Margin | 37.58% | 39.50% | 43.25% | 43.15% | 38.34% | 31.43% |
FCF Margin | 13.03% | 20.29% | 27.03% | 25.45% | 16.55% | 41.57% |
| Fiscal Year | Current | FY 2025 | FY 2024 |
|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Dividend Per Share Dividend Per Share Growth | 1.070 | 1.070 | 1.500 |
Dividend Per Share Growth | 0% | -28.67% | - |
Dividend Yield | 4.94% | 3.80% | 5.82% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 17.29 | 22.15 | 21.90 | - | - | - |
P/FCF Ratio | 49.98 | 43.13 | 35.04 | - | - | - |
PS Ratio | 6.51 | 8.75 | 9.47 | - | - | - |